CRISPR Therapeutics (CRSP) Prices 4.25M Share Common Offering at $64.50/Sh

Pre-Open 11/20: (ARAV) (I) (TGT) Higher (PDD) (URBN) (MUX) Lower (more...)

Today's Pre-Open Movers

Aravive, Inc. (Nasdaq: ARAV) 214.9% HIGHER; announced new positive data from the ongoing Phase 1b portion of the Phase 1b/2 clinical trial of AVB-500 in platinum-resistant recurrent ovarian cancer patients. The data from the first 31 patients treated at the 10mg/kg dose are maturing and affirm earlier findings on the relationship between AVB-500 levels and anti-tumor response. In this data analysis, high serum drug levels of AVB-500 were strongly predictive of anti-tumor activity with statistically significant correlation to progression-free survival (PFS; p=0.0066). PFS is the primary endpoint for... More

After-Hours Movers 11/19: (FLNT) (BCRX) (STNG) Higher; (URBN) (MUX) (ORGO) Lower (more...)

Today's After-Hours Movers

Urban Outfitters (NASDAQ: URBN) 15.6% LOWER; reported Q3 EPS of $0.56, $0.01 worse than the analyst estimate of $0.57. Revenue for the quarter came in at $987 billion versus the consensus estimate of $1 billion. Comparable Retail segment net sales increased 3%

Fluent, Inc. (NASDAQ: FLNT) 14.1% HIGHER; announced today that its Board of Directors approved a stock repurchase program. The program authorizes the repurchase of up to $5 million of shares of the Companys common stock.

McEwen Mining Inc.... More

CRISPR Therapeutics (CRSP) Announces Proposed 4.25M Common Share Offering

CRISPR Therapeutics (NASDAQ: CRSP) today announced that it is commencing an underwritten public offering of 4,250,000 common shares. In addition, the underwriters will have a 30-day option to purchase up to 637,500 additional common shares at the public offering price less the underwriting... More

CRISPR Therapeutics (CRSP) PT Raised to $80 at Canaccord Genuity

Canaccord Genuity analyst Arlinda Lee raised the price target on CRISPR Therapeutics (NASDAQ: CRSP) to $80.00 (from $72.00) while maintaining a Buy rating.

William Blair Upgrades CRISPR Therapeutics (CRSP) to Outperform

William Blair analyst Raju Prasad upgraded CRISPR Therapeutics (NASDAQ: CRSP) from Market Perform to Outperform.

For an analyst ratings summary and ratings history on CRISPR Therapeutics click here. For more ratings news on CRISPR Therapeutics click here.

Shares of CRISPR Therapeutics closed at $58.53 yesterday.

CRISPR Therapeutics (CRSP) PT Raised to $75 at Goldman Sachs

Goldman Sachs analyst Salveen Richter raised the price target on CRISPR Therapeutics (NASDAQ: CRSP) to $75.00 (from $52.00) while maintaining a Neutral rating.

CRISPR Therapeutics (CRSP) PT Raised to $100 at Roth Capital

Roth Capital analyst Tony Butler raised the price target on CRISPR Therapeutics (NASDAQ: CRSP) to $100.00 (from $65.00) while maintaining a Buy rating.

CRISPR Therapeutics (CRSP) PT Raised to $84 at Needham & Company

Needham & Company analyst Alan Carr raised the price target on CRISPR Therapeutics (NASDAQ: CRSP) to $84.00 (from $62.00) while maintaining a Buy rating.

CRISPR Therapeutics (CRSP), Vertex (VRTX) Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 for Severe Hemoglobino

CRISPR Therapeutics (NASDAQ: CRSP) and Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced positive, interim data from the first two patients with severe hemoglobinopathies treated with... More